Skip Nav Destination
You do not currently have access to this content.

GLP-1 Drugs May Play Modest Role in Cancer Prevention Available to Purchase
June 18, 2025
In two observational studies that included more than 170,000 and 86,000 patients, respectively, with obesity and/or diabetes, researchers found that glucagon-like–peptide (GLP)-1 receptor agonists may lead to modest declines in the development of more than a dozen types of obesity-related cancer, such as colorectal cancer. The findings should reassure clinicians who prescribe the medicines yet may wonder about a connection to cancer based on early studies of the drugs.
DOI:https://doi.org/10.1158/2159-8290.CD-NW2025-0055
Publisher:American Association for Cancer Research
Article Type:
News
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Purchased this content as a guest? Enter your email address to restore access.
Please enter valid email address.
Advertisement